Home › NDC Lookup › RxCUI directory › RxCUI 1607798

Deferasirox 90 MG Oral Tablet [Jadenu] — RxCUI 1607798

RxNorm drug concept · Semantic branded drug
RxCUI 1607798 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1607798
Official nameDeferasirox 90 MG Oral Tablet [Jadenu]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asJadenu 90 MG Oral Tablet
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)156 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Deferasirox: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It removes extra iron that builds up in the body. That can happen after many blood transfusions, or in certain thalassemia conditions where you don't need regular transfusions. You...
  • You take it by mouth once a day, as a tablet, a tablet mixed in liquid, or granules, depending on your product. Your dose depends on your weight and kidney function. Follow your pr...
  • Deferasirox can affect your kidneys, liver and blood counts, sometimes seriously. Tests catch problems early, and ferritin checks help make sure your iron isn't removed too far. Pl...
  • Diarrhea, nausea, vomiting, stomach pain and rash are common. Call your doctor right away for yellow skin or eyes, black or bloody stools, severe stomach pain, big changes in urina...
📖 Read our full Deferasirox guide →

🕸️ Concept Web — How Deferasirox 90 MG Oral Tablet [Jadenu] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Deferasirox 90 MG Oral Tablet [Jadenu] RxCUI 1607798

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Deferasirox 614373
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Jadenu 1607785
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Deferasirox Oral Tablet 1607783
    • Deferasirox Oral Product 1157197
    • Deferasirox Pill 1607782
    • Deferasirox Oral Tablet [Jadenu] 1607787
    • Jadenu Oral Product 1607788
    • Jadenu Pill 1607789
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Deferasirox 90 MG Oral Tablet SCD · 1607796
  • Deferasirox 90 MG SCDC · 1607795
  • Deferasirox Oral Tablet SCDF · 1607783
  • Deferasirox Oral Product SCDG · 1157197
  • Deferasirox Pill SCDG · 1607782

Brand-Name Concepts

  • Deferasirox 90 MG [Jadenu] SBDC · 1607797
  • Deferasirox Oral Tablet [Jadenu] SBDF · 1607787
  • Jadenu Oral Product SBDG · 1607788
  • Jadenu Pill SBDG · 1607789
  • Jadenu BN · 1607785

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 1607798 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0654-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15) Jadenu Novartis Pharmaceuticals Corporation 2015-03-30
00078-0655-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15) Jadenu Novartis Pharmaceuticals Corporation 2015-03-30
00078-0656-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0656-15) Jadenu Novartis Pharmaceuticals Corporation 2015-03-30
00078-0713-15 30 PACKET in 1 CARTON (0078-0713-15) / 1 GRANULE in 1 PACKE... Jadenu Novartis Pharmaceuticals Corporation 2017-05-18
00078-0720-15 30 PACKET in 1 CARTON (0078-0720-15) / 1 GRANULE in 1 PACKE... Jadenu Novartis Pharmaceuticals Corporation 2017-05-18
00078-0727-15 30 PACKET in 1 CARTON (0078-0727-15) / 1 GRANULE in 1 PACKE... Jadenu Novartis Pharmaceuticals Corporation 2017-05-18
Observed labelers: Novartis Pharmaceuticals Corporation (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.